Biomarkers in Patients With Advanced Rhabdomyosarcoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial studies tumor tissue from patients with rhabdomyosarcoma to identify important proteins and biomarkers.
Genetic: microarray analysis
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
|Official Title:||Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas|
- Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma [ Designated as safety issue: No ]
|Study Start Date:||August 2012|
|Estimated Primary Completion Date:||October 2012 (Final data collection date for primary outcome measure)|
- To investigate whether the expression of a subset of proteins (by immunohistochemistry), known to be involved in the Pax3, Pax7, and Patched-1 neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar and embryonal rhabdomyosarcomas.
OUTLINE: Iimmunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01668095
|Principal Investigator:||Charles Keller, MD||Oregon Health and Science University|